The present study showed that BSA, BW, and BMI alone did not affect the clinical outcomes of gefitinib therapy including RR, PFS, and OS in patients with advanced NSCLC harboring an EGFR mutation. Here, EGFR is linked to non-small cell lung carcinoma.